February 2014

Jim Wells, PhD

Professor

My research focuses on developing enabling technologies for protein engineering and drug discovery to understand biology and pave roads to therapeutics.

Xiaokun Shu, PhD

Associate Professor

We use principles of physics and chemistry to design technologies for biology.

Brian Shoichet, PhD

Professor

Our lab develops new methods for drug discovery, adopting two strategies to do so. On the one hand, we reduce biology to its molecular components, and seek to change how these fit together using synthetic molecules we design. On the other hand, we investigate how the biological molecules operate together, both in health and disease. Both processes involve intensive modeling and close collaboration between theory and experiment.

Daniel Santi, MD, PhD

Recall Faculty

Since my retirement in 2000, I became CEO of Kosan Biosciences. I returned to UCSF in 2007 where I served as interim Director of the UCSF CTSI and then Director of Translational Research at QB3. I became an Associate Dean of External Relationships in the School of Pharmacy in 2009, and manage the Industry Outreach Program.

Adam Renslo, PhD

Professor in Residence

My research group is engaged at the interface of chemistry and biology. As medicinal chemists, we design and synthesize small molecules that modulate disease pathology at the level of the enzyme, cell, and whole animal, with current projects in cancer, infectious disease, and neurodegeneration. As chemical biologists, we employ novel small molecule probes to better understand biological pathways and the mechanisms of small molecule therapeutics.

Paul Ortiz de Montellano, PhD

Professor

My laboratory investigates the mechanisms of heme proteins, the roles they play, and approaches for their inhibition in therapeutic situations of enzymes in both humans and bacteria that have heme groups. 

 

Susan Miller, PhD

Professor

Broadly, I use a variety of biochemical and biophysical tools to investigate protein structure/function questions spanning the range of elucidating novel aspects of catalysis in individual enzymes to understanding the interactions of proteins within a pathway and how mutations influence flux through the pathway.

Tack Kuntz, PhD

Professor Emeritus

Since retiring, I serve as a consultant for current Department faculty.

Stephen Kahl, PhD

Professor

Since retiring from UCSF, I continue to teach and coordinate PC 121 and PC 157. I am also still a member and co-chair of the Pharmaceutical Sciences Pathway Steering Committee as well as a member of several other committees.

Thomas James, PhD

Professor

I retired from full-time service at UCSF at the end of June, 2012. However, I went on Recall status a month later to do some research, which diminishes each year. I needed to  finish some projects that were still funded via grants during the initial year and continue with another funded project subesequently.

Pages